

#3

ATTORNEY DOCKET NO.: 0492479-0041 (MGH 2170 US)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Papisov, *et al.* Examiner: NYA
Serial No.: TBA Art Unit: NYA
Filing Date: January 18, 2005
Title: OXIME CONJUGATES AND METHODS FOR THEIR FORMATION
AND USE

Mail Stop: PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

STATEMENT FILED PURSUANT TO THE
DUTY OF DISCLOSURE UNDER 37 CFR §§ 1.56, 1.97 AND 1.98


Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants request consideration of this Information Disclosure Statement.

Type of Statement

The present Information Disclosure Statement is:

☒ An *original* Information Disclosure Statement; or☐ A *supplemental* Information Disclosure Statement.**Certificate of Mailing**United States Postal "Express Mail" mailing label number EV 314104180 USDate of Deposit: January 18, 2005

I hereby certify that this correspondence is being deposited with the United States Postal Service as "*Express Mail Post Office to Addressee*" service under 37 CFR 1.10 on the date indicated above and is addressed to: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450



Signature

Kathy Hart Gagnon

Typed or Printed Name of person signing certificate

Compliance with 37 CFR § 1.97

The present Information Disclosure Statement is being filed:

- ☒ Pursuant to 37 CFR § 1.97(b); no fee or certification is required:
- ☐ Within three months of the filing date of a national application other than a continued prosecution application under § 1.53(d);
 - ☒ Within three months of the date of entry of the national stage as set forth in § 1.491 in an international application;
 - ☐ Before the mailing of a first Office action on the merits; or
 - ☐ Before the mailing of a first Office action after the filing of a request for continued examination under § 1.114.
- ☐ Pursuant to 37 CFR § 1.97(c) after the dates listed above but before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311, or an action that otherwise closes prosecution in the application; Applicant hereby *either*:
- ☐ Certifies that *either*:
 - ☐ each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or
 - ☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the

knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement.; or

☐ Includes herewith the fee set forth in § 1.17(p).

☐ Pursuant to 37 CFR § 1.97(d), after the mailing date of any final action under § 1.113, a notice of allowance under § 1.311, or an action that otherwise closes prosecution in the application; Applicant hereby *both*:

☐ Certifies that *either*:

☐ each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement.; and

☐ Includes herewith the fee set forth in § 1.17(p).

Content of the Information Disclosure Statement

Applicant hereby makes of record in the above-identified application the reference(s) listed on the attached form PTO-1449 (modified). The order of presentation of the references should not be construed as an indication of the importance of the references.

Applicant includes copies of references as indicated below:

- ☒ A copy of each cited reference not indicated with a † is included, except for those for which the requirement is waived pursuant to USPTO OG Notice of 8/5/03;
- ☐ Copies of references indicated with an asterisk on the attached form PTO-1449 are not included pursuant to 37 CFR § 1.98(d) because they were previously provided to the United States Patent Office in an Information Disclosure Statement that complies with 37 CFR § 1.98(a)-(c) and was submitted in the following patent application that is relied upon in the present case for an earlier effective filing date under 35 USC § 120:

Serial Number	Filing Date	Status

- ☐ Copies of English translations of one or more non-English references are included.

Applicant hereby makes the following additional information of record in the above-identified application:

Applicant certifies that the Information Disclosure Statement *either*:

- ☒ Does not contain non-English language citations;
- ☐ Does contain non-English language citations, of which the following is a concise explanation:
- ☐ Includes one or more translations of a non-English citation.

Remarks

The submission of this Information Disclosure Statement should not be construed as a representation that a search has been made.

The submission of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in § 1.56(b) .


The submission of this Information Disclosure Statement shall not be construed as a representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited patent(s) and publication(s) has (have) been fully considered by the Patent and Trademark Office during the examination of this application; and
3. The citations for the patent(s) and publication(s) be printed on any patent which issues from this application.

Notwithstanding any statements by Applicants, the Examiner is urged to form his or her own conclusions regarding the relevance of the cited reference(s).

Respectfully submitted,



Nadège M. Lagneau, Ph.D.
Reg. No.: 51,908

PATENT DEPARTMENT
CHOATE, HALL & STEWART
Exchange Place
53 State Street
Boston, Massachusetts 02109
Tel: (617) 248-5000
Fax: (617) 248-4000

Form PTO-1449
(REV. 8-03)U.S. Department of Commerce
Patent and Trademark OfficeAttorney Docket
049247-004
(MGH 2170 US))In re Application
PTO 18 JAN 2005
Not yet assigned

INFORMATION
DISCLOSURE STATEMENT
(Use several sheets if necessary)

Applicant: Papisov *et al.*Filing Date:
January 18, 2005Group:
NYA**U.S. PATENT DOCUMENTS**

Examiner's Initials	U.S. Patent No.	Applicant	Issue Date	Class	Subclass
	† 5,342,770	Yamasaki	August 30, 1994	435	178
	† 5,605,791	Ashkenazi <i>et al.</i>	February 25, 1997	435	5
	† 5,612,037	Huebner <i>et al.</i>	March 18, 1997	424	194
	† 5,780,243	Thacker	July 14, 1998	435	7
	† 5,945,293	Siiman <i>et al.</i>	August 31, 1999	435	7.24
	† 5,591,710	Hsia	January 7, 1997	514	6
	† 6,514,500 B1	Bridon <i>et al.</i>	February 4, 2003	424	193.1

U.S. PATENT APPLICATIONS

Examiner's Initials:	Serial Number:	Applicant:	Filing Date:	Group:	Art Unit:
	†US 2002/0172689	Scott	May 18, 2001 (Pub. Date: 11/21/02)		1614

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Document No.	Country	International Publication Date	Translation	
				Yes	No
	WO 94/02068	PCT	February 3, 1994		
	WO 02/067995 A1	PCT	September 6, 2002		
	WO 02/087498 A2	PCT	November 7, 2002		

OTHER DOCUMENTS

Examiner's Initials	Citation (Including Author, Title, Date, Pertinent Pages, Etc.)
	Copy of International Search Report for PCT/US03/022584.
	Bieniarz, <i>et al.</i> , "Extended Length Heterobifunctional Coupling Agents for Protein Conjugations", <i>Bioconjugate Chem.</i> ; 7: 88-95, 1996.
	Boeckler, <i>et al.</i> , "Immunogenicity of New Heterobifunctional Cross-linking Reagents used in the Conjugation of Synthetic Peptides to liposomes", <i>Jour. of Immunological Methods</i> 191: 1-10, 1996.
	Dubowchik, <i>et al.</i> , "Monomethoxytrityl (MMT) as a Versatile Amino Protecting Group for Complex Prodrugs of Anticancer Compounds Sensitive to Strong Acids, Bases and Nucleophiles," <i>Tetrahedron Letters</i> , 38(30): 5257-5260, 1997.

† Copies of references not included – requirement waived pursuant to USPTO OG Notice of 8/5/03

Form PTO-1449
(REV. 8-03)

U.S. Department of Commerce
Patent and Trademark Office

Attorney Docket
0492479-0041
(MGH 2170 US))

In re Application
No. 10/521334
Not yet assigned

INFORMATION
DISCLOSURE STATEMENT
(Use several sheets if necessary)

Applicant: Papisov *et al.*

Filing Date:
January 18, 2005

Group:
NYA

Herrmann, *et al.*, "Peptide-functionalized Polyphenylene Dendrimers," *Tetrahedron*, **59**: 3925-3935, 2003.

Holtsberg, *et al.*, "Poly(ethylene glycol) (PEG) conjugated arginine deiminase: effects of PEG formulations on its pharmacological properties," *Journal of Controlled Release*, **80**: 259-271, 2002.

Liu *et al.*, "Strategies for the synthesis of fluorescently labeled PNA," *Tetrahedron Letters*, **41**: 6153-6156, 2000.

Pierce, "NHS-Esters-Maleimide Crosslinkers," www.piercenet.com/files/0438sm4.pdf, 2002.

Sharma, *et al.*, "Maleimide-Assisted On-resin Macrocyclization," *Tetrahedron Letters*, **37**(32): 5665-5668, 1996.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.